The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers with activating mutations commonly occuring in PIK3CA [4, 5] or AKT1 [6] activating AKT signalling and rendering cells sensitive to AKT pathway inhibitors [7–10]. This evidence concerns the gene AKT1 and cancer.